Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study-Reference-Cited by-同舟云学术

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

Published:2020-03 Issue:2 Volume:21 Page:e84-e88
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Senan Suresh,Okamoto Isamu,Lee Gyeong-won,Chen Yuanbin,Niho Seiji,Mak Gabriel,Yao Wenliang,Shire Norah,Jiang Haiyi,Cho Byoung Chul

Funder

AstraZeneca

Boehringer-Ingelheim

Taiho Pharmaceutical

Chugai

Ono Pharmaceutical

MSD

Lilly

Bristol-Myers Squibb

Astellas Pharma

Novartis

AbbVie

ISPEN

Roche

Merck

Pfizer

Bayer

MOGAM Institute

Dong-A ST

Champions Oncology

Janssen

Yuhan

Ono

Dizal Pharma

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. What's new in SCLC? A review;Oronsky;Neoplasia,2017

2. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Früh;Ann Oncol,2013

3. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial;Faivre-Finn;Lancet Oncol,2017

4. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018

5. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward the Optimal Delivery of Twice-Daily Thoracic Chemoradiation in Limited-Stage Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2024-10

2. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer;New England Journal of Medicine;2024-09-13

3. Proceedings of the 1st biannual bridging the gaps in lung cancer conference;The Oncologist;2024-09-05

4. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05

5. The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer;Oncology;2024-08-05